Contact
Please use this form to send email to PR contact of this press release:
FDA allows Phrixus’s IND for Carmeseal-MD™ (P-188 NF) in Duchenne muscular dystrophy (DMD)
TO:
Please use this form to send email to PR contact of this press release:
FDA allows Phrixus’s IND for Carmeseal-MD™ (P-188 NF) in Duchenne muscular dystrophy (DMD)
TO: